Statins increase the risk of prostate cancer: A population-based case-control study

Prostate

Volumn 71, Issue 16, 2011, Pages 1818-1824

  Chang, Chih Ching ^a   Ho, Shu Chen ^b   Chiu, Hui Fen ^c   Yang, Chun Yuh ^b,d  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

case control study; pharmacoepidemiology; prostate cancer; statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DOSE RESPONSE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TAIWAN;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PHARMACOEPIDEMIOLOGY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK FACTORS; TAIWAN;

EID: 79960016457     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21401     Document Type: Article

References (42)

1. Wong WW, Dimitroulakos J, Minden MD, Penn LZ,. HMG-CoA reductase inhibitors and the malignant cell: The statin family of drugs as triggers of tumor-specific apotosis. Leukemia 2002; 16: 508-519. (Pubitemid 34460459)
2. Hebert PR, Gaziano JM, Chan KS, Hennekens CH,. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-321. (Pubitemid 27339660)
3. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R,. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-1278.
4. Newman TB, Hulley SB,. Carcinogenicity of lipid-lowering drugs. JAMA 1996; 275: 55-60. (Pubitemid 26004257)
5. Keyomarsi K, Sandoval L, Band V, Pardee AB,. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res 1991; 51: 3602-3609.
6. Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ, Kamel-Reid S,. Microarray and biochemical analysis of lovastatin-induced apotosis of squamous cell carcinoma. Neoplasia 2002; 4: 337-346. (Pubitemid 34755844)
7. Hoque A, Chen H, Xu XC,. Statin induces apoptosis and cell growth arrest in prostate cancer cell cells. Cancer Epidemiol Biomarkers Prev 2008; 17: 88-94. (Pubitemid 351196277)
8. Weis M, Heeschen C, Glassford AJ, Cooke JP,. Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-745. (Pubitemid 34157379)
9. Park HJ, Hong D, Iruela-Arispe L, Begley U, Tang D, Galper JB,. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002; 91: 143-150. (Pubitemid 34827225)
10. Alonso DF, Farina HG, Skilton G, Gabri MR, De Lorenzo MS, Gomez DE,. Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat 1998; 50: 83-93. (Pubitemid 28438864)
11. Kusama T, Mukai M, Iwasaki T, Tatsuta M, Matsumoto Y, Akedo H, Inoue M, Nakamura H,. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 2002; 122: 308-317. (Pubitemid 34116983)
12. Shannon J, Tewoderos S, Garzotto M, Beer TM, Derenick R, Palma A, Farris PE,. Statins and prostate cancer risk: A case-control study. Am J Epidemiol 2005; 162: 318-325. (Pubitemid 41389713)
13. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R, Orav EJ, Seeger JD, Sadler MC, Quesenberry CP, Sternfeld B, Jacobsen SJ, Whitmer RA, Caan BJ,. Statin use and risk of prostate cancer in the California men's health study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218-2225. (Pubitemid 351196352)
14. Blais L, Desgagne A, LeLorier J,. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors and the risk of cancer: A nested case-control study. Arch Intern Med 2000; 160: 2363-2368.
15. Coogan PF, Rosenberg L, Palmer JR, Strom BL, Zauber AG, Shapiro S,. Statin use and the risk of breast and prostate cancer. Epidemiology 2002; 13: 262-267. (Pubitemid 34415845)
16. Coogan PF, Rosenberg L, Strom BL,. Statin use and the risk of 10 cancers. Epidemiology 2007; 18: 213-219.
17. Graaf MR, Beiderbeck AB, Egberts AC, Richel DJ, Guchelaar HJ,. The risk of cancer in users of statins. J Clin Oncol 2004; 22: 2388-2394. (Pubitemid 41115396)
18. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO, Sorensen HT, Olsen JH,. Cancer risk among statin users: A population-based cohort study. Int J Cancer 2005; 114: 643-647. (Pubitemid 40349625)
19. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC, Giovannucci E,. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825. (Pubitemid 46017933)
20. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE,. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213-2217. (Pubitemid 351196351)
21. Boudreau DM, Yu O, Buist DS, Miglioretti DL,. Statin use and prostate cancer risk in a large population-based setting. Cancer Causes Control 2008; 19: 767-774.
22. Agalliu L, Salinas CA, Hansten PD, Ostrander EA, Stanford JL,. Statin use and risk of prostate cancer: Results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250-260. (Pubitemid 352019786)
23. Haukka J, Sankila R, Klaukka T, Longvist J, Niskanen L, Tanskanen A, Wahlbeck K, Tiihonen J,. Incidence of cancer and statin usage-record linkage study. Int J Cancer 2010; 126: 279-284.
24. Kaye JA, Jick H,. Statin use and cancer risk in the General Practice Research Database. Br J Cancer 2004; 90: 635-637. (Pubitemid 38297203)
25. Murtola TJ, Tammela TL, Lahtela J, Auvinen A,. Cholesterol-lowering drugs and prostate cancer risk: A population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226-2232. (Pubitemid 351196353)
26. Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM,. Long-term follow-up of the west of Scotland Coronary Prevention Study. N Engl J Med 2007; 357: 1477-1486. (Pubitemid 47572633)
27. Chiang CW, Chen CY, Chiu HF, Wu HL, Yang CY,. Trends in the use of antihypertensive drugs by outpatients with diabetes in Taiwan, 1997-2003. Pharmacoepidemiol Drug Saf 2007; 16: 412-421.
28. Kuo HW, Tsai SS, Tiao MM, Yang CY,. Epidemiologic features of CKD in Taiwan. Am J Kidney Dis 2007; 49: 46-55.
29. Tiao MM, Tsai SS, Kuo HW, Chen CL, Yang CY,. Epidemiological features of biliary atresia in Taiwan, a national study 1996-2003. J Gastroenterol Hepatol 2008; 23: 62-66.
30. Meier CR, Scheinger RG, Kraenzlin ME, Schlege B, Jick H,. HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc 2000; 283: 3205-3210. (Pubitemid 30422037)
31. Wang PS, Solomon DH, Mogun H, Avorn J,. HMG-CoA reductase inhibitors and the risk of fractures. J Am Med Assoc 2000; 283: 3211-3216. (Pubitemid 30422038)
32. Rejnmark L, Plsen ML, Johnsen SP, Vestergaard P, Sorensen HT, Mosekilde L,. Hip fracture risk in statin users-A population-based Danish case-control study. Osteoporos Int 2004; 15: 452-458. (Pubitemid 38843173)
33. Jadhav SB, Jain GK,. Statins and osteoporosis: New role for old drugs. J Pharm Pharmacol 2006; 58: 3-18. (Pubitemid 43041991)
34. WHO. Collaborating Center for Drugs Statistics Methodology. ATC Index with DDDs 2003. Oslo: WHO; 2003.
35. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170-183. (Pubitemid 351480553)
36. Hall SA, Page ST, Travison TG, Montgomery RB, Link CL, Mckinlay JB,. Do statins affect androgen levels in men? Results from Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007; 16: 1587-1594. (Pubitemid 47294823)
37. Goldstein MR, Mascitelli L, Pezzetta F,. How statins may increase prostate cancer. Cancer Epidemiol Biomarkers Prev 2008; 17: 459. (Pubitemid 351272801)
38. Blanco-Colio LM, Villa A, Ortego M, Hernandez-Presa MA, Pascual A, Plaza JJ, Egido J,. 3-Hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors, atorvastatin and simvastatin, induce apotosis of vascular smooth muscle cells by downregulation of Bcl-2 expression and Rho A prenylation. Atherosclerosis 2002; 161: 17-26. (Pubitemid 34214817)
39. Danesh FR, Sadeghi MM, Amro N, Philips C, Zeng L, Lin S, Sahai A, Kanwar YS,. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/p21 signaling pathway: Implications for diabetic nephropathy. Proc Natl Acad Sci 2002; 99: 8301-8305. (Pubitemid 34651047)
40. Takemoto M, Liao JK,. Pleiotropic effects of 3-hydroxy-3-methylglutaryl- coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001; 21: 1712-1719. (Pubitemid 34219772)
41. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K,. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci 1999; 96: 7797-7802. (Pubitemid 29328361)
42. Shibata MA, Avanaugh C, Shibata E, Abe H, Nguyen P, Otsuki Y, Trepel JB, Green JE,. Comparative effects of lovastatin on mammary and prostate oncogenesis in transgenic mouse models. Carcinogenesis 2003; 24: 453-459. (Pubitemid 36432640)